Metastatic Pancreatic Neuroendocrine Tumor research hub
3 indexed studies · 3 currently recruiting
- recruitingPHASE1
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
This study is testing a new combination of treatments for advanced pancreatic neuroendocrine tumours. We want to see if adding sunitinib malate to lutetium Lu 177 dotatate is safe and effective. This research aims to find better ways to fight these specific cancers.
United States · Canada - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This study is testing if two drugs, trastuzumab and pertuzumab, can treat different types of cancer beyond breast cancer. These drugs work by targeting a specific change in cancer cells called HER2. It's for people aged 12 and over with HER2-positive cancers.
United Kingdom - recruiting
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
The OSPREY Registry is looking at how a device called OncoSil™ works in people with locally advanced pancreatic cancer in normal hospital care. It watches how well the device performs and if there are any side effects when used with standard chemotherapy.
Spain · United Kingdom